Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer ; volume:22 ; number:1 ; day:16 ; month:11 ; year:2020 ; pages:1-17 ; date:12.2020
Breast cancer research ; 22, Heft 1 (16.11.2020), 1-17, 12.2020
- Creator
-
Giannoudis, Athina
Malki, Mohammed Imad
Rudraraju, Bharath
Mohhamed, Hisham
Menon, Suraj
Liloglou, Triantafillos
Ali, Simak
Carroll, Jason S.
Palmieri, Carlo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01359-7
- URN
-
urn:nbn:de:101:1-2020122719060542509750
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Giannoudis, Athina
- Malki, Mohammed Imad
- Rudraraju, Bharath
- Mohhamed, Hisham
- Menon, Suraj
- Liloglou, Triantafillos
- Ali, Simak
- Carroll, Jason S.
- Palmieri, Carlo
- SpringerLink (Online service)
Other Objects (12)
Biological ageing is a key determinant in systemic sclerosis
NADase CD38 is a key determinant of ovarian aging
Issue analysis: key characteristics approach for identifying endocrine disruptors
LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide
Challenges and opportunity in mobility among older adults – key determinant identification
Knowledge as a key determinant of public support for autonomous vehicles
Histone acetylation: a key determinant of acquired cisplatin resistance in cancer
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
FABP4 as a key determinant of metastatic potential of ovarian cancer
Transcription factor expression is the main determinant of variability in gene co‐activity
Walking the First/Last Mile to/from Transit: Placemaking a Key Determinant
Biological ageing is a key determinant in systemic sclerosis
NADase CD38 is a key determinant of ovarian aging
Issue analysis: key characteristics approach for identifying endocrine disruptors
LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide
Challenges and opportunity in mobility among older adults – key determinant identification
Knowledge as a key determinant of public support for autonomous vehicles
Histone acetylation: a key determinant of acquired cisplatin resistance in cancer
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
FABP4 as a key determinant of metastatic potential of ovarian cancer
Transcription factor expression is the main determinant of variability in gene co‐activity
Walking the First/Last Mile to/from Transit: Placemaking a Key Determinant
Biological ageing is a key determinant in systemic sclerosis
NADase CD38 is a key determinant of ovarian aging
Issue analysis: key characteristics approach for identifying endocrine disruptors
LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide
Challenges and opportunity in mobility among older adults – key determinant identification
Knowledge as a key determinant of public support for autonomous vehicles
Histone acetylation: a key determinant of acquired cisplatin resistance in cancer
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
FABP4 as a key determinant of metastatic potential of ovarian cancer
Transcription factor expression is the main determinant of variability in gene co‐activity